#EACS2025 - Toshibumi Taniguch from #Japan is talking about #HIV and #Virology. Reservoir persistence remains the major obstacle. The capsid inhibitors and long-acting agents expand suppression strategies.

👩‍⚕️👨‍🔬 Why do people attend #EACS2025? Hear it straight from previous participants! Watch their testimonials and see why Paris is the place to be this October. 🌟 Register now and join the global conversation on HIV: https://loom.ly/cOdLETc #HIV #EACS2025 #Paris #MedicalCommunity

www.youtube.com/watch?v=-1rP...

20th European AIDS Conference I Hear from the participants!

YouTube video by European AIDS Clinical Society

youtube.com

Pleased to inform that a consortium of Japanese doctors has published a paper on LAI. I’m honored to be listed as a co-author. Prof. Orkin encouraged us to form the consortium. We appreciate your support. @profchloeorkin.bsky.social @toshtaniguc.bsky.social onlinelibrary.wiley.com/doi/10.1111/...

Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics

Objectives Long-acting cabotegravir plus rilpivirine (CAB+RPV) offers an alternative to daily oral therapy, but real-world data in East Asia remain scarce. This study aims to evaluate the impact of ...

onlinelibrary.wiley.com